Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
Phase Ib Trial of Enzalutamide in Combination With Radiation Therapy and LHRH Agonist Therapy in the Management of Intermediate and High-Risk Prostate Cancer
Sponsor: Astellas Pharma Inc
Listed as NCT02023463, this PHASE1 trial focuses on Adenocarcinoma of the Prostate and Recurrent Prostate Cancer and remains ongoing. Sponsored by Astellas Pharma Inc, it has been updated 15 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
15 versions recorded-
Dec 2025 — Present [monthly]
Active Not Recruiting PHASE1
-
Nov 2024 — Dec 2025 [monthly]
Active Not Recruiting PHASE1
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Nov 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
▶ Show 10 earlier versions
-
Mar 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE1
-
Sep 2022 — Mar 2023 [monthly]
Active Not Recruiting PHASE1
-
Jan 2021 — Sep 2022 [monthly]
Active Not Recruiting PHASE1
-
Oct 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
-
May 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE1
-
Aug 2018 — May 2019 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE1
-
Aug 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Aug 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Apr 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Inc
- Medivation, Inc.
- Thomas Jefferson University
For direct contact, visit the study record on ClinicalTrials.gov .